On October 15, 2026, the Stochastic Oscillator for ELMD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 56 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 79%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ELMD's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ELMD just turned positive on September 17, 2026. Looking at past instances where ELMD's MACD turned positive, the stock continued to rise in 28 of 41 cases over the following month. The odds of a continued upward trend are 68%.
Following a +1.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELMD advanced for three days, in 183 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELMD as a result. In 71 of 118 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The 50-day moving average for ELMD moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The Aroon Indicator for ELMD entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. ELMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.247) is normal, around the industry mean (2.908). P/E Ratio (20.000) is within average values for comparable stocks, (2.616). ELMD's Projected Growth (PEG Ratio) (103.010) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.080) is also within normal values, averaging (40.124).
The Moving Average Convergence Divergence (MACD) for INBS turned positive on October 16, 2026. Looking at past instances where INBS's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INBS's RSI Oscillator exited the oversold zone, 40 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 70 cases where INBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBS advanced for three days, in 153 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
INBS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day moving average for INBS crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for INBS entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.921) is normal, around the industry mean (2.908). P/E Ratio (-0.181) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.688) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. INBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ELMD | INBS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 57 | 100 | |
SMR RATING 1..100 | 42 | 100 | |
PRICE GROWTH RATING 1..100 | 58 | 50 | |
P/E GROWTH RATING 1..100 | 76 | 20 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INBS's Valuation (49) in the null industry is somewhat better than the same rating for ELMD (100) in the Medical Specialties industry. This means that INBS’s stock grew somewhat faster than ELMD’s over the last 12 months.
ELMD's Profit vs Risk Rating (57) in the Medical Specialties industry is somewhat better than the same rating for INBS (100) in the null industry. This means that ELMD’s stock grew somewhat faster than INBS’s over the last 12 months.
ELMD's SMR Rating (42) in the Medical Specialties industry is somewhat better than the same rating for INBS (100) in the null industry. This means that ELMD’s stock grew somewhat faster than INBS’s over the last 12 months.
INBS's Price Growth Rating (50) in the null industry is in the same range as ELMD (58) in the Medical Specialties industry. This means that INBS’s stock grew similarly to ELMD’s over the last 12 months.
INBS's P/E Growth Rating (20) in the null industry is somewhat better than the same rating for ELMD (76) in the Medical Specialties industry. This means that INBS’s stock grew somewhat faster than ELMD’s over the last 12 months.
| ELMD | INBS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 60% | N/A |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| Advances ODDS (%) | 22 days ago 71% | 1 day ago 84% |
| Declines ODDS (%) | 1 day ago 66% | 6 days ago 90% |
| BollingerBands ODDS (%) | N/A | 7 days ago 90% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELMD’s FA Score shows that 0 FA rating(s) are green while INBS’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELMD’s TA Score shows that 4 TA indicator(s) are bullish while INBS’s TA Score has 5 bullish TA indicator(s).
ELMD (@Medical/Nursing Services) experienced а -2.53% price change this week, while INBS (@Medical/Nursing Services) price change was +0.66% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.46%. For the same industry, the average monthly price growth was -8.91%, and the average quarterly price growth was -9.61%.
ELMD is expected to report earnings on Nov 10, 2026.
INBS is expected to report earnings on Nov 05, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OEI | 26.26 | 0.13 | +0.51% |
| Optimized Equity Income ETF (OEI) | |||
| DWSH | 5.77 | 0.03 | +0.45% |
| AdvisorShares Dorsey Wright Short ETF (DWSH) | |||
| GINN | 79.73 | N/A | N/A |
| Innovate Equity ETF (GINN) | |||
| SPTS | 28.71 | -0.01 | -0.03% |
| State Street SPDR Portfolio Short Term Treasury ETF (SPTS) | |||
| AVSF | 45.69 | -0.04 | -0.09% |
| Avantis Short-Term Fixed Income ETF (AVSF) | |||
A.I.dvisor indicates that over the last year, INBS has been loosely correlated with IVF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if INBS jumps, then IVF could also see price increases.
| Ticker / NAME | Correlation To INBS | 1D Price Change % | ||
|---|---|---|---|---|
| INBS | 100% | +2.00% | ||
| IVF - INBS | 63% Loosely correlated | +4.23% | ||
| ELMD - INBS | 31% Poorly correlated | -0.07% | ||
| NVNO - INBS | 27% Poorly correlated | +4.02% | ||
| ITGR - INBS | 27% Poorly correlated | +0.04% | ||
| PFSA - INBS | 26% Poorly correlated | -3.32% | ||
More | ||||